[Stellenbosch University] San Francisco -- The PETITE-DTG study evaluated dolutegravir (DTG) -- a drug that revolutionized HIV treatment in adults and children -- in infants less than 28 days old, using a pediatric 5 mg dispersible tablet (DTG-DT) and a novel 5 mg oral dispersible Film (DTG-Film).
